
FoundationOne® Heme is an advanced DNA and RNA based comprehensive genomic profiling test that enables detailed molecular characterization of hematologic malignancies. When evaluated together with the lymphoma solution of Signatera™, this integrated approach provides comprehensive support across the oncology care continuum, from molecular diagnosis and treatment selection to post-treatment minimal residual disease (MRD) monitoring.
| Technical Specifications | |
| Method: NGS – Hybrid Capture | Coverage: |
| Intended Use: Hematologic malignancies and solid tumors | |
| Gene Coverage: 406 DNA genes + 265 RNA genes | Sequencing Depth: ~500× |
| Variant Types Detected: SNVs, Indels, CNVs, Fusions, and Gene Rearrangements | Genomic Signatures: TMB (Tumor Mutational Burden), MSI (Microsatellite Instability) |
| Translocation Detection: High-sensitivity DNA and RNA based detection | Sample Types: FFPE tissue, Peripheral Blood, Bone Marrow |
| Turnaround Time: Approximately 14–21 days | Reporting: Clinically significant variants with Variant Allele Frequency (VAF %) reporting |
| Additional Features: • Supports identification of targeted therapy options and prognostic assessment • Provides insights to support immunotherapy response prediction | |
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, Şişli / Istanbul
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00
The content provided on this site is intended for informational purposes only and is not a substitute for professional medical advice or diagnosis. Always seek the advice of a qualified healthcare provider for any medical evaluation, diagnosis, or treatment.
All rights reserved © 2026. Explicit Consent Statement | Last Updated: 27.04.2026 14:00 / mowaffak@hotmail.com
I acknowledge that I have read and understood the Privacy Notice provided by Nesiller Genetic Laboratories, acting as the data controller. The Privacy Notice clearly and comprehensively explains the identity of the data controller, the categories of personal data to be processed, the purposes of processing, the recipient groups to whom personal data may be transferred, the methods and legal grounds for data collection, and my rights as a data subject. I have also been informed that more detailed information is available in the Personal Data Retention and Destruction Policy and in the records maintained within the VERBIS system at the address indicated.
In addition to the matters described in the Privacy Notice, I freely give my explicit consent, with full awareness of the meaning, legal consequences, and potential future implications of this declaration, to the processing of my name, surname, email address, telephone number, company name, country, city, and address solely for the purposes of product and service promotions, gifts, discounts, new opportunities and special offers, announcements, advertisements, campaigns, personalized marketing activities, event invitations, and special occasion greetings, and for being contacted by email and SMS in accordance with the Law on the Regulation of Electronic Commerce and its applicable secondary legislation.
I further consent to the sharing of these personal data with companies providing SMS and email delivery services and marketing consultancy services with which Nesiller Genetic Laboratories has contractual relationships, solely for the purposes specified above.